Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

News Conference News ACC 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Yael L. Maxwell

May 15, 2021

Emergent CABG in Acute MI: Survival Better Despite Increasingly Risky Patients

News Conference News ACC 2021

Emergent CABG in Acute MI: Survival Better Despite Increasingly Risky Patients

May 15, 2021

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

News Conference News ACC 2021

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

Michael O'Riordan

May 11, 2021

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

News Conference News ACC 2020

TICO: Ticagrelor Monotherapy After 3 Months of DAPT Curbs Bleeding in Stented ACS Patients

March 31, 2020

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

Thin Struts and ‘Pro-Healing’ Layer: Combo Stent Sees Success at 1 Year

News Conference News ACC 2018

Thin Struts and ‘Pro-Healing’ Layer: COMBO Stent Sees Success at 1 Year

Yael L. Maxwell

March 11, 2018

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

Live From Washington: ACC 2017, Day One

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

March 17, 2017

Two-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Presentation ACC 2014

Two-Year Outcome of a Randomized Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Presenter: Masahiro Natsuaki

March 31, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

March 31, 2014

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

March 11, 2013

One-Year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Presentation ACC 2013

One-Year Outcome of a Trial Comparing Second Generation Drug-eluting Stents Using Either Biodegradable Polymer or Durable Polymer

Presenter: Masahiro Natsuaki

March 09, 2013

News Conference News ACC 2013

Is Nobori NEXT? Biodegradable-Polymer DES Noninferior to EES

March 09, 2013

News Conference News ACC 2012

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

March 26, 2012

News Conference News ACC 2012

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

March 24, 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.